Reply to thread

Our entire defense is to tell doctors we cannot compare the two drugs and pivot back to our 8 year old messaging? 

As engaging and inspiring as that is, maybe we should get advice from a company who has launched a highly competitive me too drug.

This is not a successful plan.

Docs will want to know the similarities, differences and where they should use both. We lose the LTC scripts without crushable so where do we gain ground?